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Background
The role of probiotics in prevention of allergic disease is
still unclear; efficacy may depend on the timing, dose,
duration and specific probiotic used. Using a double blind
randomized placebo-controlled trial (Australian New
Zealand Clinical Trials Registry: ACTRN12607000518460),
we have shown that in a high risk birth cohort, maternal
supplementation from 35 weeks gestation until 6 months
if breastfeeding and infant supplementation from birth
until 2 years with Lactobacillus rhamnosus HN001
(HN001) (6 x 109 cfu/day) halved the cumulative preva-
lence of eczema at 2 and 4 years. Bifidobacterium animalis
subsp lactis HN019 (HN019) (9 x 109/cfu day) had no
significant effect.
Objective
To determine whether differences in effects of HN001
and HN019 on eczema persist to age 6 years, and to
investigate effects on sensitization.
Methods
Standard procedures were used to assess eczema (The
UK Working Party’s criteria), eczema severity
(SCORAD), atopic sensitization (skin prick tests (SPT),
total and specific IgE) and standard questions used for
asthma, wheeze and rhinoconjunctivitis.
Results
HN001 was associated with significantly lower cumulative
prevalence of eczema (HR=0.56, 95% CI 0.39-0.80),
SCORAD≥10 (HR=0.69, 0.49-0.98) and SPT sensitization
(HR=0.69, 95% CI 0.48-0.99). The point prevalence of
eczema (RR=0.66, 95% CI 0.44-1.00), SCORAD≥10
(RR=0.62, 95% CI 0.38-1.01) and SPT sensitization
(RR=0.72, 95% CI 0.53-1.00) were also reduced among
children taking HN001. HN019 had no significant effect
on any outcome.
Conclusion and clinical relevance
This study provides evidence for the efficacy of the pro-
biotic Lactobacillus rhamnosus HN001 in preventing the
development of eczema and possibly also atopic sensiti-
zation in high risk infants to age 6 years. The absence of
a similar effect for HN019 indicates that benefits may be
species-specific.
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